Sangamo Therapeutics (NASDAQ:SGMO) Given New $10.00 Price Target at HC Wainwright

Sangamo Therapeutics (NASDAQ:SGMO) had its price target increased by HC Wainwright from $5.00 to $10.00 in a report published on Tuesday, Benzinga reports. The firm currently has a buy rating on the biopharmaceutical company’s stock.

Separately, StockNews.com assumed coverage on shares of Sangamo Therapeutics in a report on Sunday, July 28th. They set a “sell” rating on the stock. One investment analyst has rated the stock with a sell rating, three have given a hold rating and one has issued a buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $4.33.

Sangamo Therapeutics Trading Up 24.1 %

Sangamo Therapeutics stock opened at $2.16 on Tuesday. The stock has a 50-day moving average price of $1.02 and a two-hundred day moving average price of $0.74. Sangamo Therapeutics has a 12 month low of $0.29 and a 12 month high of $2.30. The company has a market capitalization of $449.76 million, a PE ratio of -1.57 and a beta of 1.10.

Sangamo Therapeutics (NASDAQ:SGMO) last issued its quarterly earnings data on Tuesday, August 6th. The biopharmaceutical company reported ($0.17) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.01). Sangamo Therapeutics had a negative net margin of 2,033.69% and a negative return on equity of 273.25%. The business had revenue of $0.36 million during the quarter, compared to the consensus estimate of $11.40 million. As a group, analysts predict that Sangamo Therapeutics will post -0.47 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of SGMO. Acadian Asset Management LLC increased its stake in Sangamo Therapeutics by 4.0% in the first quarter. Acadian Asset Management LLC now owns 4,943,260 shares of the biopharmaceutical company’s stock valued at $3,311,000 after purchasing an additional 192,385 shares in the last quarter. Renaissance Technologies LLC increased its position in Sangamo Therapeutics by 58.8% in the 2nd quarter. Renaissance Technologies LLC now owns 4,126,577 shares of the biopharmaceutical company’s stock valued at $1,479,000 after buying an additional 1,528,600 shares in the last quarter. Marshall Wace LLP raised its stake in Sangamo Therapeutics by 56.3% during the 2nd quarter. Marshall Wace LLP now owns 576,219 shares of the biopharmaceutical company’s stock worth $207,000 after buying an additional 207,476 shares during the period. Mirae Asset Global Investments Co. Ltd. bought a new position in Sangamo Therapeutics in the first quarter worth approximately $331,000. Finally, Vontobel Holding Ltd. grew its stake in Sangamo Therapeutics by 412.3% in the third quarter. Vontobel Holding Ltd. now owns 300,000 shares of the biopharmaceutical company’s stock valued at $259,000 after acquiring an additional 241,440 shares during the period. Institutional investors and hedge funds own 56.93% of the company’s stock.

Sangamo Therapeutics Company Profile

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.